Muvon Therapeutics announces First Patient Enrolled in Phase II Clinical Study

27-10-2022 – Muvon Therapeutics announces First Patient Enrolled in Phase II Clinical Study in Female Patients with Stress Urinary Incontinence using Novel Regenerative Cell Therapy

Wysszurich keyvisual muvon

Muvon Therapeutics AG, an innovative clinical-stage biotechnology company, today announced that the first patient with Stress Urinary Incontinence has been enrolled as part of the planned Phase II clinical trial (SUISSE MPC 2-Study) using its novel proprietary cell therapy platform.